Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2025-04-11 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于召开2024年度暨2025年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the upcoming 2024 annual and 2025 first quarter performance explanation meeting (业绩说明会) scheduled for April 21, 2025. It provides details on the meeting time, location, participation method, and contact information. The document does not contain actual financial data or detailed financial analysis but serves to inform investors about the event where such information will be discussed. The document length is short (1473 characters) and it is clearly an announcement rather than the report or transcript itself. Therefore, it fits the category of an Investor Presentation announcement or a Call Transcript announcement. However, since it is specifically about a performance explanation meeting (业绩说明会), which is typically a form of investor presentation, the best fit is Investor Presentation (IP).
2025-04-11 Chinese
长春百克生物科技股份公司2025年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2025 first extraordinary shareholders meeting of Changchun Baike Biotechnology Co., Ltd. It details the meeting date, attendance, voting results, and legal witness statements. There is no financial data or report content, only the voting results and procedural compliance information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2025-04-07 Chinese
北京植德律师事务所关于长春百克生物科技股份公司2025年第一次临时股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and voting results of the 2025 first extraordinary general meeting (临时股东会) of Changchun Baike Biotechnology Co., Ltd. It details the legality of the meeting's call, attendance, voting procedures, and results. The document does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting process and voting outcomes. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms the legitimacy of the shareholder meeting procedures.
2025-04-07 Chinese
长春百克生物科技股份公司2025年第一次临时股东会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the "2025 First Extraordinary General Meeting of Shareholders" of Changchun Baike Biotechnology Co., Ltd. It contains detailed meeting instructions, agenda, and a proposal regarding the election of a non-independent director to the board. The content focuses on the organization and conduct of a shareholders' meeting, including voting procedures and candidate information. There is no financial data, earnings information, or audit content. The document is clearly a set of meeting materials for a shareholders' meeting, not the meeting minutes or voting results. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2025-03-26 Chinese
长春百克生物科技股份公司关于召开2025年第一次临时股东会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2025 first extraordinary general meeting of shareholders for Changchun Baike Biotechnology Co., Ltd. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements, audit results, or detailed financial data. It is an announcement of a shareholder meeting rather than the meeting materials or results. The document length is 2764 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual or Extraordinary General Meeting, including notices of meetings.
2025-03-20 Chinese
长春百克生物科技股份公司关于补选第六届董事会非独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a non-independent director to the company's board. It details the resignation of a previous director and the nomination of a new candidate, including the candidate's biography and compliance with regulatory requirements. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to changes in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length is short and focused solely on this topic, confirming the classification.
2025-03-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.